News
3d
Pharmaceutical Technology on MSNVertex and NHS England agree reimbursement for AlyftrekVertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...
NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...
Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...
The Irish News on MSN4d
Hundreds of cystic fibrosis patients become eligible for ‘life-changing’ therapyThe National Institute for Health and Care Excellence (Nice) has given the green light for the NHS to give patients Alyftrek, ...
A once-a-day pill health experts are calling 'life-changing' will be offered to hundreds of people living with cystic ...
Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...
Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results